Literature DB >> 28427701

Multiple sclerosis showing elevation of adenosine deaminase levels in the cerebrospinal fluid.

Miharu Samuraki1, Kenji Sakai2, Yasuko Odake3, Mitsuhiro Yoshita3, Kouichi Misaki4, Mitsutoshi Nakada4, Masahito Yamada1.   

Abstract

An 80-year-old man developed dysarthria, quadriplegia, sensory disturbance and ataxia in all limbs. Brain and spinal magnetic resonance imaging (MRI) revealed multiple enhanced lesions. Cerebrospinal fluid (CSF) levels of adenosine deaminase (ADA) remarkably elevated. Tuberculosis DNA was not detected, and tuberculosis was not cultured either in the CSF. Brain biopsy revealed the inflammatory demyelinating lesions. With the diagnosis of multiple sclerosis, corticosteroid therapy resulted in rapid improvement of his symptoms and MRI abnormalities. CSF levels of ADA also decreased. Multiple sclerosis should be included in differential diagnosis of disorders with ADA elevation in the CSF.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adenosine deaminase; Brain biopsy; Cerebrospinal fluid; Multiple sclerosis; Tuberculosis

Mesh:

Substances:

Year:  2017        PMID: 28427701     DOI: 10.1016/j.msard.2017.02.005

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  5 in total

Review 1.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

2.  ELTD1 as a biomarker for multiple sclerosis: Pre-clinical molecular-targeted studies in a mouse experimental autoimmune encephalomyelitis model.

Authors:  Rheal A Towner; Nataliya Smith; Michelle Zalles; Sara Morris; MacKenzie Toliver; Debra Saunders; Megan Lerner; Gaurav Kumar; Robert C Axtell
Journal:  Mult Scler Relat Disord       Date:  2021-01-22       Impact factor: 4.339

Review 3.  Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple Sclerosis.

Authors:  María José Zarzuelo Romero; Cristina Pérez Ramírez; María Isabel Carrasco Campos; Almudena Sánchez Martín; Miguel Ángel Calleja Hernández; María Carmen Ramírez Tortosa; Alberto Jiménez Morales
Journal:  J Pers Med       Date:  2021-04-23

4.  The impaired distribution of adenosine deaminase isoenzymes in multiple sclerosis plasma and cerebrospinal fluid.

Authors:  Barbara Kutryb-Zajac; Ada Kawecka; Fionä Caratis; Krzysztof Urbanowicz; Alicja Braczko; Tomomi Furihata; Bartosz Karaszewski; Ryszard T Smolenski; Aleksandra Rutkowska
Journal:  Front Mol Neurosci       Date:  2022-09-20       Impact factor: 6.261

5.  A Single Nucleotide ADA Genetic Variant Is Associated to Central Inflammation and Clinical Presentation in MS: Implications for Cladribine Treatment.

Authors:  Mario Stampanoni Bassi; Fabio Buttari; Ilaria Simonelli; Luana Gilio; Roberto Furlan; Annamaria Finardi; Girolama Alessandra Marfia; Andrea Visconti; Andrea Paolillo; Marianna Storto; Stefano Gambardella; Rosangela Ferese; Marco Salvetti; Antonio Uccelli; Giuseppe Matarese; Diego Centonze; Francesca De Vito
Journal:  Genes (Basel)       Date:  2020-09-30       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.